Drug intelligence / Profile preview

KROPHAN

Development stage: Unknown
Lead developer: Repha
Modality: Small Molecules
Administration: Oral

Overview

KROPHAN is a dietary supplement developed by Repha GmbH Biologische Arzneimittel, primarily composed of bladderwrack (*Fucus vesiculosus*), a brown algae. It serves as a natural source of iodine, with each film-coated tablet providing 100 µg of iodine. The product is intended to support normal thyroid function and hormone production, particularly in individuals with increased iodine requirements, such as pregnant or nursing women. It is classified as a nutritional supplement (Nahrungsergänzungsmittel) rather than a pharmaceutical drug and is produced using ecologically sustainable wild harvesting methods that comply with European Pharmacopoeia standards.

Brand names: KROPHANKROPHAN Blasentangtabletten
Other names: KROPHAN-RephaBlasentangtablettenFucus vesiculosus tablets

Targets

THR (Thyroid hormone receptor)

Beyond the preview

Go deeper on KROPHAN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KROPHAN.

Explore the full profile